Managing Insomnia After Starting Spravato
Start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, as this is the evidence-based standard for managing insomnia disorder regardless of cause, while recognizing that insomnia is a documented side effect of esketamine that occurs in approximately 7% of patients. 1, 2, 3
Understanding the Problem
The FDA label explicitly lists insomnia as one of the symptoms that Spravato may produce, alongside anxiety, dysphoria, disorientation, and hallucinations 2. However, the clinical picture is nuanced: meta-analysis data shows that esketamine does not significantly increase the odds of treatment-emergent insomnia compared to placebo (OR = 1.07,95% CI 0.68-1.69) 3, and some studies even demonstrate that esketamine improves sleep disturbance scores more than placebo by day 8 of treatment 4.
This apparent contradiction likely reflects that:
- Most TRD patients already have baseline sleep disturbance (65% moderate/severe, 25% mild) 4
- Esketamine may paradoxically improve sleep in some while causing insomnia in others
- Your insomnia may represent either a direct drug effect or inadequate depression response
Treatment Algorithm
Step 1: Assess Timing and Pattern
- If insomnia started within the first 1-2 weeks: This may resolve spontaneously as many patients show sleep improvement by day 8 4
- If insomnia persists beyond 2 weeks or worsens: Proceed with active intervention
- Document: Sleep onset difficulty vs. sleep maintenance problems vs. early morning awakening
Step 2: Implement CBT-I (First-Line)
CBT-I is the gold-standard treatment with moderate-strength evidence for improving global sleep outcomes and most specific sleep parameters 1. This multicomponent approach includes:
- Stimulus control: Use bed only for sleep and sex; leave bedroom if not asleep within 20 minutes
- Sleep restriction: Limit time in bed to actual sleep time, then gradually increase
- Cognitive restructuring: Address dysfunctional beliefs about sleep and catastrophizing
- Relaxation training: Progressive muscle relaxation or breathing exercises
- Sleep hygiene education: Consistent sleep schedule, avoid caffeine after noon, dark/cool bedroom
CBT-I typically requires 4-8 sessions with a trained therapist and shows sustained benefits beyond treatment completion 1.
Step 3: Consider Multicomponent Behavioral Therapy
If full CBT-I is not accessible, brief behavioral therapy for insomnia (combining sleep restriction, stimulus control, and relaxation without the cognitive component) has low-to-moderate strength evidence for improving sleep outcomes 1.
Step 4: Evaluate Esketamine Response
At 4 weeks (end of induction phase), assess whether esketamine is providing meaningful antidepressant benefit 2. This is critical because:
- If depression is not responding adequately, the insomnia may reflect inadequate treatment
- Evidence shows 1-point improvement in sleep at day 8 increases probability of antidepressant response by 26% and remission by 28% 4
- Poor sleep response may predict poor overall treatment response
Step 5: Pharmacologic Considerations (Short-Term Only)
If behavioral interventions are insufficient and esketamine is otherwise effective for depression, short-term supplementary medication may be considered 1. However:
- The American Academy of Sleep Medicine recommends psychological/behavioral interventions first, with only short-term supplementary medication 1
- Pharmacologic options carry risks (cognitive/behavioral changes, falls, potential dependence) 5
- This should be time-limited (weeks, not months) while behavioral interventions take effect
Step 6: Dosage Adjustment
Consider dose reduction from 84 mg to 56 mg if tolerability is the primary issue 2. The FDA label allows for dosage adjustment based on tolerability, and lower doses may reduce side effects while maintaining efficacy.
Critical Monitoring Points
- Do not discontinue esketamine abruptly if it's providing depression benefit, as this may worsen both depression and potentially cause withdrawal symptoms with prolonged use 2
- Reassess at week 4 and week 8: These are natural decision points in the esketamine protocol 2
- Track both sleep and depression symptoms: Use sleep diaries (not polysomnography, which is not indicated) 1, 5
Common Pitfalls to Avoid
- Assuming all insomnia is drug-induced: Most TRD patients have baseline sleep disturbance that may improve with esketamine 4
- Jumping to sleep medications: This bypasses the most effective long-term treatment (CBT-I) 1
- Ignoring the 2-hour post-dose monitoring requirement: Ensure you're not engaging in activities that could worsen sleep hygiene after sessions 2
- Not addressing next-day sedation: Patients must avoid driving until after a restful sleep following each dose 2
When to Reconsider Esketamine
If insomnia is severe, persistent beyond 4-8 weeks, and esketamine is not providing meaningful depression benefit, discuss with your prescriber whether to:
- Switch to alternative TRD treatments
- Modify the dosing schedule (though evidence for this is limited)
- Ensure concurrent oral antidepressant is optimized 2
The key principle: prioritize the treatment that addresses the life-threatening condition (treatment-resistant depression) while aggressively managing the insomnia with evidence-based behavioral interventions, not by reflexively discontinuing an effective antidepressant.